-- 
Israeli Stocks: Brainsway, ICL, Koor Industries, Strauss, Teva

-- B y   G w e n   A c k e r m a n
-- 
2011-07-28T14:29:39Z

-- http://www.bloomberg.com/news/2011-07-28/israeli-stocks-brainsway-koor-industries-strauss-group-teva.html
Israel ’s TA-25 Index fell 1.8
percent, the most since June 15, to 1,232.74 at the 4:30 p.m.
close in  Tel Aviv . Investors traded about 2.25 billion shekels
($658 million) in shares and convertible securities, according
to Tel Aviv Stock Exchange data.  The measure dropped 2.4 percent this week, trimming the
gain this month to 0.7 percent.  The following stocks rose or fell today. Symbols are in
parentheses.  Brainsway Ltd. (BRIN)   climbed for the first time in four
days, increasing 1.5 percent to 25.44 shekels. The maker of
devices to treat neurological disorder received a “fast track”
status from the U.S. Food and Drug Administration for its
product for Major Depressive Disorder.  Israel Chemicals Ltd. (ICL)  , which extracts minerals
from the Dead Sea to make fertilizer, rose for the third day
this week, advancing 1.1 percent to 58 shekels. Potash Corp. of
Saskatchewan Inc., the world’s largest fertilizer producer,
raised its full-year earnings forecast after reporting second-
quarter earnings that beat analysts’ estimates as crop-nutrient
prices gained.  Koor Industries Ltd. (KOR)   dropped 3.9 percent to 56.50
shekels, the lowest level since March 2009. Credit Suisse Group
AG said second-quarter profit fell 52 percent on lower earnings
from trading. Koor holds 3.1 percent of Credit Suisse, according
to Bloomberg data.  Strauss Group Ltd. (STRS)   lost the most in since Jan.
30, declining 3.2 percent to 51.61 shekels. The Ministry of
Industry, Trade and Labor said Israel will open its dairy market
to more competition and imports. Strauss derives about a fifth
of its revenue from dairy products.  Teva Pharmaceutical Industries Ltd. (TEVA)   dropped 2.2
percent to 157.10 shekels, the lowest since May 1. The world’s
largest generic drugmaker said third-quarter profit will miss
analysts’ estimates even as it kept its full-year outlook,
leaving analysts wondering where the company will find more than
$1 billion in added revenue in the fourth quarter.  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  